Mode
Text Size
Log in / Sign up

CT radiomics and transcriptomics predict chemotherapy response in advanced laryngeal cancer

CT radiomics and transcriptomics predict chemotherapy response in advanced laryngeal cancer
Photo by Buddha Elemental 3D / Unsplash
Key Takeaway
Consider radiomics for risk stratification in laryngeal cancer, but await prospective validation.

This retrospective cohort study analyzed 161 advanced laryngeal cancer patients treated with induction chemotherapy to assess the predictive value of CT radiomics features, transcriptomics, and clinical features for chemotherapy response. No comparator was reported, and follow-up duration was not specified. The study setting and publication type were not reported.

Main results showed that a Rad-score had an AUC of 0.715 in the training set and 0.707 in the validation set for discriminating chemotherapy response. Independent predictors of response included Rad-score, gap invasion, and validation, with Rad-score having an odds ratio of 2.89 (95% CI: 1.29–6.48, P=0.010). A Random Forest model combining these features achieved an AUC of 0.914 in the training set, 0.856 in the validation set, and 0.810 in an external test set. Absolute numbers for these outcomes were not reported.

Safety and tolerability data, including adverse events and discontinuations, were not reported. Key limitations include the need for prospective studies to validate clinical utility, as noted in the input. The study suggests this approach may enable precise risk stratification and personalized treatment decisions, potentially sparing non-responders from ineffective therapy, but this is based on observational data and requires further confirmation. Funding and conflicts of interest were not reported.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundPredicting response to induction chemotherapy (IC) in advanced laryngeal cancer (LC) remains a clinical challenge. This study aimed to develop a non-invasive, interpretable model integrating CT radiomics and clinical features to predict chemotherapy outcomes.MethodsWe retrospectively analyzed 161 advanced LC patients treated with IC. From pre-treatment CT images, 1,321 radiomics features were extracted, and a radiomics score (Rad-score) was constructed using LASSO regression. Transcriptomic analysis explored the biological basis of Rad-score. Independent predictors were identified via multivariate logistic regression and used to build five machine learning models. Model performance was evaluated using AUC, accuracy, and specificity. SHAP analysis was applied to interpret the optimal model.ResultsFour robust radiomics features were selected to construct the Rad-score. The Rad-score demonstrated satisfactory discrimination with an Area Under the Curve (AUC) of 0.715 in the training set and 0.707 in the validation set. In multivariate analysis, the Rad-score (Odds Ratio [OR]=2.89, 95% CI: 1.29–6.48, P = 0.010), gap invasion and validation were identified as independent predictors of chemotherapy response. Among the machine learning models, the Random Forest model achieved the best performance, yielding an AUC of 0.914 in the training set, 0.856 in the validation set, and 0.810 in the external test set. Decision curve analysis confirmed the clinical utility of the model. SHAP analysis confirmed Rad-score and fat space invasion as core predictors, with synergistic effects.ConclusionsWe developed a highly accurate and interpretable Random Forest model that integrates radiomics and clinical features to predict IC response in advanced LC. This tool enables precise risk stratification and personalized treatment decisions, sparing non-responders from ineffective therapy. Prospective studies are needed to validate its clinical utility.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.